TAK1 signaling is a potential therapeutic target for pathological angiogenesis

Zhu, Linxin; Lama, Suraj; Tu, Leilei; Dusting, Gregory J.; Wang, Jiang-Hui; Liu, Guei‐Sheung

doi:10.1007/s10456-021-09787-5

Cited by 24 publications

(14 citation statements)

References 136 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAK1 is an emerging therapeutic target for pathologic angiogenesis since it closely engages in several important angiogenic activities. 123 Wang et al 124 developed a novel eye drop formulation based on GNPs to encapsulate the selective TAK1 inhibitor 5Z-7-oxozeaenol to treat CNV in a rodent model. Topical administration of GNP-encapsulated 5Z-7-oxozeaenol led to significantly greater suppression of CNV in a mouse model than the free form of 5Z-7-oxozeaenol.…”

Section: Applications Of Ons In Cnv Therapymentioning

confidence: 99%

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

Zhang¹,

Yin²,

Zhao³

et al. 2022

IJN

View full text Add to dashboard Cite

Corneal neovascularization (CNV) is an ocular pathological change that results from an imbalance between angiogenic factors and antiangiogenic factors as a result of various ocular insults, including infection, inflammation, hypoxia, trauma, corneal degeneration, and corneal transplantation. Current clinical strategies for the treatment of CNV include pharmacological treatment and surgical intervention. Despite some degree of success, the current treatment strategies are restricted by limited efficacy, adverse effects, and a short duration of action. Recently, gene-based antiangiogenic therapy has become an emerging strategy that has attracted considerable interest. However, potential complications with the use of viral vectors, such as potential genotoxicity resulting from long-term expression and nonspecific targeting, cannot be ignored. The use of ocular nanosystems (ONS) based on nanotechnology has emerged as a great advantage in ocular disease treatment during the last two decades. The potential functions of ONS range from nanocarriers, which deliver drugs and genes to target sites in the eye, to therapeutic agents themselves. Various preclinical studies conducted to date have demonstrated promising results of the use of ONS in the treatment of CNV. In this review, we provide an overview of CNV and its current therapeutic strategies and summarize the properties and applications of various ONS related to the treatment of CNV reported to date. Our goal is to provide a comprehensive review of these considerable advances in ONS in the field of CNV therapy over the past two decades to fill the gaps in previous related reports. Finally, we discuss existing challenges and future perspectives of the use of ONS in CNV therapy, with the goal of providing a theoretical contribution to facilitate future practical growth in the area.

show abstract

Section: Applications Of Ons In Cnv Therapymentioning

confidence: 99%

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

Zhang¹,

Yin²,

Zhao³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Under physiological conditions, angiogenesis is intricately and precisely regulated by multiple molecules and mechanisms that allow the formation of highly tissue-specific, structured and hierarchical vascular networks to sustain the physiological processes of embryonic development, growth and tissue repair ( Lai et al, 2021 ; Martin and Gurevich, 2021 ; Narasimhan et al, 2021 ). However, tumor cells are able to release large amounts of vascular endothelial growth factor (VEGF) and inhibit the secretion of angiogenesis inhibitory factor, which unbalances the regulatory mechanism of angiogenesis, resulting in rapid, uncontrolled proliferation of tumor neovascularization and a large, abnormally disordered replenishment network ( Liu Y. et al, 2021 ; Uemura et al, 2021 ; Zhu et al, 2021 ). CircRNAs can also be involved in the malignant invasion and metastasis of GBM by affecting angiogenesis ( Figure 3A ).…”

Section: Biological Function and Molecular Mechanism Of Circular Rnas In Glioblastomamentioning

confidence: 99%

Research Progress of circRNAs in Glioblastoma

Guo

Piao

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are a class of single-stranded covalently closed non-coding RNAs without a 5′ cap structure or 3′ terminal poly (A) tail, which are expressed in a variety of tissues and cells with conserved, stable and specific characteristics. Glioblastoma (GBM) is the most aggressive and lethal tumor in the central nervous system, characterized by high recurrence and mortality rates. The specific expression of circRNAs in GBM has demonstrated their potential to become new biomarkers for the development of GBM. The specific expression of circRNAs in GBM has shown their potential as new biomarkers for GBM cell proliferation, apoptosis, migration and invasion, which provides new ideas for GBM treatment. In this paper, we will review the biological properties and functions of circRNAs and their biological roles and clinical applications in GBM.

show abstract

“…Myocardial infarction (MI) is the irreversible death of cardiac cells secondary to prolonged ischemia and can transit to heart failure which accounts for one of the leading causes of death worldwide [1,2]. Angiogenesis, the new blood vessel formation, has been shown to have the potential to rescue ischemic myocardia early after MI and also is critical to prevent long-term cardiac remodeling to prevent heart failure development [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

HSPA12A Stimulates p38/ERK-AP-1 Signaling to Promote Angiogenesis and Is Required for Functional Recovery Postmyocardial Infarction

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Angiogenesis plays a critical role in wound healing postmyocardial infarction (MI). However, there is still a lack of ideal angiogenic therapeutics for rescuing ischemic hearts clinically, suggesting that a more understanding regarding angiogenesis regulation is urgently needed. Heat shock protein A12A (HSPA12A) is an atypical member of the HSP70 family. Here, we demonstrated that HSPA12A was upregulated during endothelial tube formation, a characteristic of in vitro angiogenesis. Intriguingly, overexpression of HSPA12A promoted in vitro angiogenic characteristics including proliferation, migration, and tube formation of endothelial cells. By contrast, deficiency of HSPA12A impaired myocardial angiogenesis and worsened cardiac dysfunction post-MI in mice. The expression of genes related to angiogenesis (VEGF, VEGFR2, and Ang-1) was decreased by HSPA12A deficiency in MI hearts of mice, whereas their expression was increased by HSPA12A overexpression in endothelial cells. HSPA12A overexpression in endothelial cells increased phosphorylation levels and nuclear localization of AP-1, a transcription factor dominating angiogenic gene expression. Also, HSPA12A increased p38 and ERK phosphorylation levels, whereas inhibition of p38 or ERKs diminished the HSPA12A-promoted AP-1 phosphorylation and nuclear localization, as well as VEGF and VEGFR2 expression in endothelial cells. Notably, inhibition of either p38 or ERKs diminished the HSPA12A-promoted in vitro angiogenesis characteristics. The findings identified HSPA12A as a novel angiogenesis activator, and HSPA12A might represent a viable strategy for the management of myocardial healing in patients with ischemic heart diseases.

show abstract

TAK1 signaling is a potential therapeutic target for pathological angiogenesis

Cited by 24 publications

References 136 publications

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

Research Progress of circRNAs in Glioblastoma

HSPA12A Stimulates p38/ERK-AP-1 Signaling to Promote Angiogenesis and Is Required for Functional Recovery Postmyocardial Infarction

Contact Info

Product

Resources

About